Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

58.80 +1.01 (+1.75%)
Streaming Delayed Price Updated: 3:05 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
News headline image
Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159 ↗
Celldex Therapeutics Inc (NASDAQ: CLDX) got a boost Friday with a data readout from Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021 ↗
Upgrades For FB Financial Corp (NYSE: 
Via Benzinga
News headline image
Stock Profile: Roche Holding AG ADR ↗
Roche maintains a healthy balance sheet with $13.9 billion in cash and investments and $12.5 billion in long-term debt as of 12/31/2020. 
Via Talk Markets
News headline image
WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients ↗
The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients... 
Via Benzinga
News headline image
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today ↗
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ:... 
Via Benzinga
News headline image
New Month And Half Year ↗
Welcome to H2. In theory, if markets did well in H1 they tend to close the year up. 
Via Talk Markets
News headline image
End Of June ↗
Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made. 
Via Talk Markets
Topics Initial Public Offering
News headline image
Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-... 
Via Benzinga
News headline image
Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact ↗
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it... 
Via Benzinga
Topics Intellectual Property
News headline image
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer ↗
Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (... 
Via Benzinga
News headline image
Roche's Enspryng Wins European Approval For Spinal Cord, Optic Nerve Inflammation Disorder ↗
The European Commission has approved Roche Holding AG's (OTC: RHHBY) injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder... 
Via Benzinga
News headline image
FDA Gives Emergency Use Nod For Roche's Arthritis Drug Against Severe COVID-19 ↗
The 
Via Benzinga
News headline image
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
News headline image
Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children
From Genentech
Via Business Wire
News headline image
Crazy Thursday ↗
Today the US stock market went ballistic probably because of a higher joblessness level than expected. 
Via Talk Markets
News headline image
Here's Why Arcus Biosciences Stock Is Rising Today ↗
Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise. 
Via The Motley Fool
News headline image
Arcus Biosciences Rockets, But Vague Update In Cancer Study Divides Analysts ↗
Arcus Biosciences offered a vague update on its lung cancer regimens Wednesday, but RCUS stock rocketed on Thursday. 
Via Investor's Business Daily
News headline image
FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
News headline image
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
News headline image
Reconsidered Boom ↗
The US markets tried to repeat the big rise from yesterday, and appears to have succeeded. 
Via Talk Markets
News headline image
Roche's Alzheimer's Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study Shows ↗
Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE: LLY) and Roche Holding AG's (OTC: RHHBY) failed to improve symptoms of Alzheimer's... 
Via Benzinga
News headline image
The First Day Of Summer And Prime Day ↗
The bull is back in business today. 
Via Talk Markets
News headline image
Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod ↗
The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's (OTC: RHHBY) Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat... 
Via Benzinga
News headline image
Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer ↗
The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway... 
Via Benzinga
News headline image
Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy ↗
Synlogic Inc (NASDAQ: SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC: RHHBY) for the discovery of Synthetic Biotic... 
Via Benzinga
News headline image
Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license... 
Via Benzinga
News headline image
Continued Uncertainty ↗
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
News headline image
Dreary Day ↗
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
News headline image
JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients ↗
A combination of Johnson & Johnson’s (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG’s (OTC: RHHBY) Venclexta/... 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.